Skip to main navigation
Skip to main content
  • Investors & Media
    • Overview
    • Newsroom
    • Events
    • Financial Information
    • Stock Information & Analyst Coverage
    • FAQs
  • Careers
  • Partnerships & Business Development
  • Contact Us
  • Investors & Media
    • Overview
    • Newsroom
    • Events
    • Financial Information
    • Stock Information & Analyst Coverage
    • FAQs
  • Our Company
    • About Us
    • Leadership Team
    • Board of Directors
    • Ethics and Compliance
    • Corporate Governance & Committee Composition
  • Patients
    • Cholesterol Education
    • Unmet Need
    • Patient Advocacy and Resources
  • Products
  • Science
    • Scientific Advisory Board
    • Pipeline
    • Clinical Trials
    • Expanded Access
    • Grants
/investor-relations/newsroom

Newsroom

Esperion Announces Closing of $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Mar 22, 2023
PDF Version
Esperion Announces $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Mar 20, 2023
PDF Version
International Lipid Expert Panel (ILEP) Recommends Use of Bempedoic Acid Ahead of PCSK9 Inhibitors in Managing Lipid Disorders and Cardiovascular Risk
Mar 08, 2023
PDF Version
Landmark CLEAR Outcomes Study Demonstrates NEXLETOL® (bempedoic acid) Tablet is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad Population of Both Primary Prevention and Secondary Prevention Patients
Mar 04, 2023
PDF Version
Esperion Launches New Scientific Website
Feb 24, 2023
PDF Version

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • …
  • Next page next ›
  • Last page last »

-

Media Information

To speak with a member of our PR team, or to schedule an interview, please contact Esperion Corporate Communications by phone at +1 734-864-6774, or by email at corporateteam@esperion.com.

Leadership Information

Page Tools

Our Company

  • Our Company
    • About Us
    • Leadership Team
    • Board of Directors
    • Ethics and Compliance
    • Corporate Governance & Committee Composition

Patients

  • Patients
    • Cholesterol Education
    • Unmet Need
    • Patient Advocacy and Resources

Products

  • Products

Science

  • Science
    • Scientific Advisory Board
    • Pipeline
    • Clinical Trials
    • Expanded Access
    • Grants

Careers

  • Careers

Partnerships & Business Development

  • Partnerships & Business Development

Investors & Media

  • Investors & Media
    • Overview
    • Newsroom
    • Events
    • Financial Information
    • Stock Information & Analyst Coverage
    • FAQs

Contact Us

  • Contact Us

All trademarks and trade names are the property of their respective owners.

© 2023 Esperion Therapeutics, Inc. All rights reserved. 05/20 US-CRP-2000082

Utility

  • Privacy Policy
  • Terms of Use
  • Accessibility Statement
  • Social Media Community Guidelines

Search

Share this page